The Scottish Medicines Consortium has accepted the following drugs for use within NHS Scotland:
- atazanavir (Reyataz), co-administered with low dose ritonavir and other antiretrovirals, for HIV in children 6 years of age and older
- etonogestrel (Nexplanon), for long-acting contraception
- denosumab (Prolia), for osteoporosis in postmenopausal women at increased risk of fractures. Use is restricted to patients with a bone mineral density T-score < -2.5 and ≥ -4.0 in whom oral bisphosphonates are unsuitable due to contraindication, intolerance or inability to comply with the administration instructions.
- moxifloxacin infusion (Avelox IV), for the treatment of community acquired pneumonia when other commonly recommended antibacterial agents are inappropriate. Use is restricted to cases where it is recommended by a microbiologist or infectious disease specialist.
- tacrolimus granules for suspension (Modigraf), to prevent transplant rejection in kidney, liver or heart allograft recipients and to treat allograft rejection resistant to other immunosuppressants. Use is restricted to patients in whom tacrolimus is an appropriate immunosuppressant and who require small dose changes (less than 500 microgram), or who are seriously ill and unable to swallow tacrolimus capsules.
The SMC rejected dexamethasone intravitreal implant (Ozurdex) and prucalopride (Resolor) following full submissions. Gefitinib (Iressa) and ranolazine (Ranexa) were rejected following resubmissions. No submissions were received for fondaparinux sodium (Arixtra) or diclofenac spray (Mobigel).